Beijing Boren Hospital Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2020
NCT04325841
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Beijing Boren Hospital | Beijing Gaobo Boren Hospital | Bejing Goboard Boren Hospital

Active Ingredients

Drugs in Phase 2 Trials (3)

cd19 car-t cells (1 trial)

cd22 car-t cells (1 trial)

cd7 car-t cell (2 trials)

Drugs in Phase 1 Trials (2)

cd5 car-t cells (1 trial)

lcar-t2c car-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5